158 Views

CANADIAN CARDIOVASCULAR SOCIETY

CCS

CCC

ACC

CLINICAL CARDIOLOGIST

CCS/ACC JOINT PLENARY: MULTIDISCIPLINARY HEART FAILURE TEAM: MEETING FUTURE DEMANDS / PLÉNIÈRE COMMUNE CCS/ACC : ÉQUIPE MULTIDISCIPLINAIRE D'INSUFFISANCE CARDIAQUE : RÉPONDRE AUX BESOINS FUTURS

ROUNDTABLE PANEL DISCUSSION AND Q&A (CCC-190)

Saturday, October 28, 2023

14:45 – 15:00 EST

Location: Palais, 517D

Target Audience: Academic center clinicians, Community Cardiologists, Trainees, Nurses, Allied health professionals

Co-Chair(s)

Cathie Biga (she/her/hers)

Vice President
American College of Cardiology
Sean Virani, MD, MSc, MPH, FRCPC, FCCS (he/him/his)

Vice-President | Medical and Academic Affairs | Provincial Health Services Authority
UBC
St. Paul's Hospital | Providence Health Care

Presenter(s)

Aws Almufleh, MBBS, MPH, FRCPC

Cardiologist and Physician Lead of the Heart Function Clinic
Kingston Health Sciences Centre
Queen's University
Biykem Bozkurt

Editor in Chief, JACC: Heart Failure The Mary and Gordon Cain Chair and Professor of Medicine Associate Provost of Faculty Affairs, Senior Associate Dean of Faculty Development Director, Winters Center for Heart Failure Research Assoc. Director, Cardiovascular Research Institute Vice-Chair of Medicine, Baylor College of Medicine Medicine Chief, DeBakey VA Medical Center
Baylor College of Medicine
Baylor College of Medicine
Rodolfo K. Pike, RN BN MN NP

NP heart function clinic
CCS/CCCN
Easternhealth
Ricky D. Turgeon, BSc(Pharm), ACPR, PharmD

Assistant Professor / Pharmacist
University Of British Columbia
University of British Columbia

Disclosure(s):

Aws Almufleh, MBBS, MPH, FRCPC: Bayer: Consultant/Advisory Board (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Servier: Consultant/Advisory Board (Terminated, September 20, 2022)

Biykem Bozkurt: Abiomed, American Regent, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Daiichi Sankyo, Johnson & Johnson, Hanger Institute, Merck, Occlutech, Regeneron, Roche, Sanofi, sc Pharmaceuticals, Vifor, Zoll/ Respicardia: Consultant/Advisory Board (Ongoing)

Rodolfo K. Pike, RN BN MN NP: Astra Zeneca: Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer-Ingelheim: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Speaker/Honoraria (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Ricky D. Turgeon, BSc(Pharm), ACPR, PharmD: No financial relationships to disclose

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

discuss the trajectory of the future HF clinical care burden (Professional);
recognize short-term and long-term system solutions to the HF provider crisis (Health Advocate);
identify the recognized subspecialties and allied health disciplines within HF practice (Collaborator); and
propose training solutions and team to the HF provider crisis (Leader).

4 talks will highlight the looming HF provider crisis from the perspective of interdisciplinary team members. Each talk will include 1 polling question for interactivity. The session will conclude with a roundtable panel discussion of existing and potential North American solutions to meet the upcoming HF care requirements.